Non-Hodgkin Lymphoma (NHL)

1 Credit / Cardiology, Neurology

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1.5 Credit / Hematologic Cancer, Oncology

Closing Gaps in CLL Care: Managed Care Insights and Strategies

1.0 Credit / Oncology, Hematology, Hematologic Cancer

ASH Annual Meeting Coverage: Highlighting the Recent Updates in TKI Use in the Treatment of CML – Insights and Application for Managed Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Hematologic Cancer, Hematology, Oncology

Overcoming Operational and Clinical Barriers in Multiple Myeloma: Managed Care Strategies for Antibody-Based Regimens

More News

FDA | Image Credit: wladimir1804 - stock.adobe.com

July 18th 2025

FDA Delivers a CRL to Glofitamab for Relapsed/Refractory DLBCL

The FDA determined the data from STARGLO did not provide sufficient evidence to support approving glofitamab-gxbm (Columvi) in combination with gemcitabine and oxaliplatin to treat relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

$refractory mantle cell lymphoma | Image: Kite$

July 17th 2025

After CAR T in Mantle Cell Lymphoma, Choices and a Robust Pipeline

Mantle cell lymphoma treatment offers options if patients relapse after CAR T-cell therapy, from bispecific antibodies, antibody drug conjugates, and other emerging therapies.

DLBCL | Image: Atlas of Haematological Cytology

July 16th 2025

Lack of CD20 Expression Worsens Outcomes for Bispecifics in R/R DLBCL

Real-world analysis reveals that undetectable CD20 expression worsens outcomes for patients treated with epcoritamab and glofitamab bispecific antibodies for their diffuse large B-cell lymphoma (DLBCL).

July 7th 2025

Cases Show How Epcoritamab Revived CAR T Cells After Relapse in DLBCL

In R/R Marginal Zone Lymphoma, 90% Alive at 2 Years After Liso-Cel

Marginal zone lymphoma | Image: Atlas of Hematological Cytology

June 24th 2025

In a cohort of TRANSCEND FL, the chimeric antigen receptor T-cell therapy liso-cel showed a 95% overall response rate in relapsed marginal zone lymphoma, offering hope for improved patient outcomes in challenging cases.

Cleveland Clinic Main Campus | Image: Cleveland Clinic

June 19th 2025

Optimizing Advanced Cancer Therapies and Addressing Logistical, Financial Challenges

Laura Joszt, MA

Coverage from IVBM Cleveland, held May 15, 2025.

large B-cell lymphoma | Image credit: Cleveland Clinic

June 17th 2025

Epcoritamab Plus Chemoimmunotherapy Yields 87% Response Rate in R/R DLBCL; 65% Proceed to Transplant

Results show the regimen of epcoritamab plus R-ICE could serve most patients as a bridge to either autologous stem cell transplant or CAR T-cell therapy.

Follicular lymphoma | Image: The Follicular Lymphoma Foundation

June 14th 2025

A Look at Those With Durable Responses to Epcoritamab in LBCL

A post-hoc analysis of EPCORE-NHL-1 was presented at ASCO.

Ian W. Flinn, MD, PhD | Image credit: OneOncology

June 10th 2025

Fixed-Duration SC Mosunetuzumab Shows 83% PFS at 1 Year in Untreated HTB Follicular Lymphoma

Subcutaneous mosunetuzumab shows promising efficacy and safety in high-tumor burden follicular lymphoma, paving the way for outpatient treatment options.

The findings show that ctDNA is worthy of additional study as a tool for assessing risk and treatment response in large B-cell lymphoma, the authors concluded. | Image credit: Connect world - stock.adobe.com

June 7th 2025

Biomarker-Adapted Treatment Effective in High-Risk LBCL

Jared Kaltwasser

TP53 aberrations and circulating tumor DNA burden were found to be predictors of poor outcomes in high-risk patients with large B-cell lymphoma.

The findings suggest assessment of CD20 may be an important factor in determining treatment options in B-cell lymphomas. | Image credit: kalpis - stock.adobe.com

May 28th 2025

CD20 Levels May Impact BsAb Response in B-Cell Lymphomas

Jared Kaltwasser

The findings suggest assessment of CD20 may be an important factor in determining treatment options in B-cell lymphomas.

$The data suggest BsAbs are safe and effective in many patients with relapsed or refractory LBCL following CAR T-cell therapy. | Image credit: jarun011 - stock.adobe.com$

May 23rd 2025

Early Relapse After CAR T-Cell Therapy Linked With Poor BsAb Outcomes in LBCL

Jared Kaltwasser

Elevated LDH and higher international prognostic index were also predictors of poor outcomes on bispecific antibodies, investigators found.

Overall, there were 36 factors identified as having a prognostic impact on at least 1 clinical outcome. | Image Credit: laszlo - stock.adobe.com

May 16th 2025

Review Identifies Top Prognostic Factors in Third-Line or Later DLBCL

AJMC Contributor

A systematic review and subsequent expert review gave comprehensive insight into prognostic factors for patients receiving treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

May 12th 2025

Collaboration Advances Lymphoma Care: Andrew Evens, DO

Kyle Munz Andrew Evens, DO

Multidisciplinary efforts help promote the success of clinical trials and innovation for patients with various forms of lymphoma, explained Andrew Evens, DO.

May 2nd 2025

Expanding Resources, Clinical Knowledge to Enhance AYA NHL Care: Andrew Evens, DO

Kyle Munz Andrew Evens, DO

To better treat adolescent and young adult (AYA) patients with various subtypes of Hodgkin and non-Hodgkin lymphomas (NHL), Andrew Evens, DO, speaks to the importance of primary care, screening access, and research.

Multigenerational | Image Credit: © DisobeyArt-stock.adobe.com

April 16th 2025

DLBCL Outcomes Vary Sharply for Patients 80 Years and Older

A majority of cases of diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma globally, are diagnosed in patients 65 years and older; these patients are a heterogeneous group, and few studies have investigated how their outcomes are influenced by patient characteristics and care management regimens.

CAR T in NHL | Image Credit: © LASZLO-stock.adobe.com

April 3rd 2025

Radiation Bridging Therapy Boosts CAR T Outcomes in R/R LBCL

In this comparative analysis, patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) received bridging therapy via radiation or systemic treatment while their chimeric antigen receptor T-cell therapy (CAR T) was being manufactured.

March 24th 2025

Amid NIH Cuts, ASH Expands Eligibility for Midcareer Research Awards

The American Society of Hematology (ASH) was already looking to expand its Bridge Grant program when changes to the National Institutes of Health (NIH) funding landscape created greater urgency.

CAR T | Image Credit: © Funny-stock.adobe.com

March 21st 2025

Overcoming CAR T Manufacturing Failure in LBCL

Data incorporated for this study were collected from 9 centers in the UK focused on third-line and beyond chimeric antigen receptor (CAR) T-cell administration in patients with relapsed/refractory large B-cell lymphoma (LBCL).

Patients with R/R transformed DLBCL have modest 4-year event free and overall survival rates under 50%, making disease management a persistent challenge | SuriyaPhoto - stock.adobe.com

March 14th 2025

Atezolizumab, Immunogenic Chemotherapy Combination Shows Promise for DLBCL Treatment

An early pilot trial suggests that combining atezolizumab (tecectriq) with rituximab (Rituxan), gemcitabine (gemzar) and oxaliplatin (eloxatin; GemOx; R-GemOx+Atezo) could be a well-tolerated and effective treatment option in non-Hodgkin lymphoma.

BalanceIssues | Image Credit: © Bangkok Click Studio-stock.adobe.com

February 28th 2025

Falls, Balance Issues Signal Higher ICANS Risk in NHL

Tim Cortese

Adverse physical functions were indicative of reduced survival and increased risk of immune effector cell–associated neurotoxicity syndrome (ICANS) in patients with non-Hodgkin lymphoma (NHL) previously treated with chimeric antigen receptor T-cell therapy.

Bispecific antibody | Image credit: MD Anderson

February 19th 2025

Banner Year for Bispecifics as Therapies Advance Into the Community Setting

Ryan Flinn

A rituximab and lenalidomide combination (R-len) for treating non-Hodgkin lymphoma (NHL) could play a greater role in future clinical trials | image credit: MQ-Illustrations - stock.adobe.com

February 18th 2025

Real-World Data Support Rituximab Plus Lenalidomide in NHL

A rituximab and lenalidomide combination for treating non-Hodgkin lymphoma (NHL) could play a greater role in future clinical trials.

FDA approval | Image Credit: © wladimir1804 - stock.adobe.com

Published: February 12th 2025 | Updated: February 12th 2025

FDA Approves Brentuximab Vedotin, Lenalidomide, Rituximab Triplet for R/R LBCL

Interim data from the ECHELON-3 trial previously showed that adding brentuximab vedotin to lenalidomide and rituximab improved overall survival among patients who have relapsed or refractory large B-cell lymphoma (R/R LBCL).

Non-Hodgkin Lymphoma wordcloud | Image Credit: © kalpis-stock.adobe.com.jpeg

February 7th 2025

Refining Remission Assessment in Aggressive B-Cell Lymphomas

Despite research showing the benefits of circulating tumor DNA as an indicator of disease remission in B-cell lymphoma, hurdles that include availability and cost remain to its widespread implementation.

Non-HodgkinLymphoma | Image Credit: © enterlinedesign-stock.adobe.com

January 30th 2025

SynKIR-310 Dosing for B-NHL Begins in CELESTIAL-301 Trial

Jordyn Sava

The CELESTIAL-301 trial evaluating SynKIR-310, a novel chimeric antigen receptor T-cell therapy, has dosed its first patient with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL).

Extranodal NHL is not uncommon, comprising over 30% of NHL cases | image credit: Prostock Studio - stock.adobe.com

January 29th 2025

Study Expands Knowledge of Prognostic Markers in Extranodal NHL

Extranodal non-Hodgkin lymphoma (NHL) makes up over one-third of NHL cases, yet remains understudied and in need of deeper research considerations.

There remains a need for more diagnostic accuracy in cases of soft tissue NHL | image credit: phonlamaiphoto - stock.adobe.com

January 27th 2025

MRI, sIL-2R Combination Showcases Great Diagnostic Accuracy for Soft Tissue NHL

Serum soluble interleukin-2 receptor (sIL-2R) levels have been a great diagnostic tool for non-Hodgkin lymphoma (NHL) and could provide further benefits for distinguishing soft-tissue NHL from other soft tissue tumors.

January 17th 2025

FDA Grants 2 Traditional Approvals for Acalabrutinib